Physician profile
Clive E Roberson
NPI 1497748123
$1,582.98
in general payments reported to CMS, 2019-2025
13 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $99.13 · 2021: $241 · 2022: $85.27 · 2023: $312 · 2024: $275 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $482.82 | 2021-2025 | |
| Csl Behring | $241.29 | 2019-2025 | Haegarda |
| Teva Pharmaceuticals USA, INC. | $179.37 | 2019-2021 | |
| Glaxosmithkline, LLC. | $166.60 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $163.99 | 2019-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $103.57 | 2021-2023 | Orladeyo |
| Leo Pharma INC. | $56.85 | 2024 | Adbry |
| Takeda Pharmaceuticals U.S.A., INC. | $45.68 | 2021-2023 | Hyqvia |
| Novartis Pharmaceuticals Corporation | $35.00 | 2023 | |
| Janssen Pharmaceuticals, INC | $33.22 | 2025 | Spravato |
| Astrazeneca Pharmaceuticals Lp | $28.63 | 2019-2021 | |
| Biocryst Pharmaceuticals, INC. | $23.61 | 2020 | |
| Aimmune Therapeutics, INC. | $22.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clive Roberson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.